(Q37829671)

24 August 2017

1 reference

title

Omalizumab: Anti-IgE therapy in allergy (English)

1 reference

24 August 2017

Matthias Volkmar Kopp

series ordinal

1

1 reference

24 August 2017

1 April 2011

1 reference

Current Allergy and Asthma Reports

24 August 2017

1 reference

24 August 2017

11

1 reference

24 August 2017

2

1 reference

24 August 2017

101-106

1 reference

https://scigraph.springernature.com/pub.10.1007/s11882-010-0173-4

24 August 2017

0 references

cites work

Targeting IgE with monoclonal antibodies: the future is now.

1 reference

https://api.crossref.org/works/10.1007%2FS11882-010-0173-4

Effect of omalizumab on symptoms of seasonal allergic rhinitis: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-010-0173-4

Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-010-0173-4

Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-010-0173-4

Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-010-0173-4

Omalizumab rapidly decreases nasal allergic response and FcepsilonRI on basophils.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-010-0173-4

The anti-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-010-0173-4

Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-010-0173-4

Omalizumab, a recombinant humanized anti-IgE antibody, reduces asthma-related emergency room visits and hospitalizations in patients with allergic asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-010-0173-4

The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-010-0173-4

Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-010-0173-4

Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-010-0173-4

Improvement in quality of life with omalizumab in patients with severe allergic asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-010-0173-4

Omalizumab, an anti-IgE antibody, in the treatment of adults and adolescents with perennial allergic rhinitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-010-0173-4

Omalizumab (Xolair) in children with seasonal allergic rhinitis: leukotriene release as a potential in vitro parameter to monitor therapeutic effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-010-0173-4

Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-010-0173-4

Combination of omalizumab and specific immunotherapy is superior to immunotherapy in patients with seasonal allergic rhinoconjunctivitis and co-morbid seasonal allergic asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-010-0173-4

Omalizumab for treatment of ABPA exacerbations in CF patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-010-0173-4

Treatment of allergic bronchopulmonary aspergillosis (ABPA) in CF with anti-IgE antibody (omalizumab).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-010-0173-4

Steroid-sparing effect of omalizumab for allergic bronchopulmonary aspergillosis and cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-010-0173-4

Successful treatment of allergic bronchopulmonary aspergillosis with recombinant anti-IgE antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-010-0173-4

Mast cell survival and activation by IgE in the absence of antigen: a consideration of the biologic mechanisms and relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-010-0173-4

Two cases of severe refractory chronic idiopathic urticaria treated with omalizumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-010-0173-4

Effective treatment of refractory severe heat urticaria with omalizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-010-0173-4

Recalcitrant atopic dermatitis treated with omalizumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-010-0173-4

Anti-Immunoglobulin E Treatment of Patients with Recalcitrant Physical Urticaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-010-0173-4

Effective treatment of therapy-resistant chronic spontaneous urticaria with omalizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-010-0173-4

Omalizumab is effective and safe in the treatment of Japanese cedar pollen-induced seasonal allergic rhinitis

21 January 2018

1 reference

12 December 2020

Elevated serum total IgE--a potential marker for severe chronic urticaria

1 reference

12 December 2020

Steroid dependency despite omalizumab treatment of ABPA in cystic fibrosis

1 reference

12 December 2020

Omalizumab improves asthma-related quality of life in patients with severe allergic asthma

1 reference

12 December 2020

Failure of omalizumab for treatment of severe adult atopic dermatitis

1 reference

12 December 2020

Maintenance of remission with low-dose omalizumab in long-lasting, refractory chronic urticaria

1 reference

12 December 2020

Efficacy of anti-IgE therapy in patients with atopic dermatitis

1 reference

12 December 2020

Low-dose anti-IgE therapy in patients with atopic eczema with high serum IgE levels

1 reference

12 December 2020

Down-regulation of Fc(epsilon)RI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody.

1 reference

12 December 2020

Anti-IgE for chronic asthma in adults and children

1 reference

12 December 2020

Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE-mediated) asthma

1 reference

12 December 2020

Safety of anti-IgE treatment with omalizumab in children with seasonal allergic rhinitis undergoing specific immunotherapy simultaneously

1 reference

12 December 2020

Efficacy of combination treatment with anti-IgE plus specific immunotherapy in polysensitized children and adolescents with seasonal allergic rhinitis

1 reference

12 December 2020

Partial improvement of solar urticaria after omalizumab

1 reference

12 December 2020

Effectiveness of omalizumab in a patient with severe asthma and atopic dermatitis

1 reference

12 December 2020

The effect of anti-IgE treatment on in vitro leukotriene release in children with seasonal allergic rhinitis

1 reference

12 December 2020

10.1007/S11882-010-0173-4

Identifiers

DOI

1 reference

24 August 2017

1 reference

PubMed ID

21243454